NivolumabRecent, repeatedEvidence- NCT07877194 · Summit Therapeutics · Phase 2 · live · comparator · “Nivolumab combined with Ipilimumab” · registered Sep 2026
- NCT07494435 · Zhejiang Haichang Biotech Co., Ltd. · Phase 2 · live · background · “Nivolumab (240 mg)” · registered Mar 2026
- NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Nivolumab” · registered Mar 2024
- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Nivolumab” · registered Aug 2023
- NCT05678673 · Exelixis · Phase 3 · live · background · “Nivolumab” · registered Dec 2022
| Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015) | 66 studies | 78 studies | background 17 · comparator 2 |
pembrolizumabRecent, repeatedEvidence- NCT07749586 · Arvinas Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
- NCT06716853 · genenta science · Phase 2 · background · “Pembrolizumab” · registered Nov 2024
- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Aug 2023
- NCT05805501 · Hoffmann-La Roche · Phase 2 · comparator · “Pembrolizumab” · registered Mar 2023
- NCT05620134 · Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 2 · live · background · “Pembrolizumab” · registered Nov 2022
| Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015) | 66 studies | 77 studies | comparator 1 · background 12 |
IpilimumabRecent, repeatedEvidence- NCT07877194 · Summit Therapeutics · Phase 2 · live · comparator · “Nivolumab combined with Ipilimumab” · registered Sep 2026
- NCT07227415 · Pfizer · Phase 2 · live · background · “Ipilimumab” · registered Nov 2025
- NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Ipilimumab” · registered Mar 2024
- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Ipilimumab” · registered Aug 2023
- NCT04203901 · CoImmune · Phase 2 · background · “Nivolumab+Ipilimumab” · registered Dec 2019
| Bristol-Myers Squibb91% of its industry studiesUS: Bristol-Myers Squibb (FDA 2011)EU: Bristol-Myers Squibb (EMA 2011) | 44 studies | 55 studies | background 7 · comparator 1 |
AxitinibRecent, repeatedEvidence- NCT05805501 · Hoffmann-La Roche · Phase 2 · background · “Axitinib” · registered Mar 2023
- NCT05522231 · HUTCHMED · Phase 3 · comparator · “axitinib / everolimus” · registered Aug 2022
- NCT05256472 · Akeso · Phase 2 · background · “axitinib” · registered Jan 2022
- NCT02667886 · X4 Pharmaceuticals · Phase 2 · background · “axitinib” · registered Jan 2016
- NCT02639182 · Astellas Pharma Inc · Phase 2 · comparator · “Axitinib” · registered Dec 2015
| Pfizer80% of its industry studiesUS: Pfizer (FDA 2012)EU: off-patent, 1 generic authorized | 33 studies | 00 studies | background 3 · comparator 3 |
BevacizumabRecent, repeatedEvidence- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Bevacizumab” · registered Aug 2023
- NCT05824975 · GI Innovation, Inc. · Phase 2 · live · background · “bevacizumab” · registered Mar 2023
- NCT03961698 · Infinity Pharmaceuticals, Inc. · Phase 2 · live · background · “Bevacizumab” · registered Apr 2019
- NCT02187302 · Lumos Pharma, Inc. · Phase 2 · background · “Bevacizumab” · registered Jun 2014
- NCT00719264 · Novartis · Phase 2 · background · “bevacizumab” · registered Jul 2008
| Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others | 22 studies | 33 studies | background 6 |
PaclitaxelRecent, repeatedEvidence- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Paclitaxel” · registered Aug 2023
- NCT05824975 · GI Innovation, Inc. · Phase 2 · live · background · “paclitaxel” · registered Mar 2023
- NCT04198766 · Inhibrx Biosciences, Inc · Phase 2 · live · background · “Paclitaxel 200mg/m2” · registered Dec 2019
- NCT03693612 · GlaxoSmithKline · Phase 2 · comparator · “Paclitaxel” · registered Oct 2018
- NCT02599324 · AbbVie · Phase 2 · background · “paclitaxel” · registered Nov 2015
| Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed | 22 studies | 33 studies | background 4 · comparator 1 |
cabozantinibRecent, repeatedEvidence- NCT07293351 · Bristol-Myers Squibb · Phase 2 · live · background · “Cabozantinib” · registered Dec 2025
- NCT06716853 · genenta science · Phase 2 · background · “Cabozantinib” · registered Nov 2024
- NCT04586231 · Merck & Co., Inc · Phase 3 · live · comparator · “Cabozantinib” · registered Oct 2020
- NCT04300140 · Aravive, Inc. · Phase 2 · background · “Cabozantinib (Cabo)” · registered Mar 2020
- NCT03729245 · Nektar Therapeutics · Phase 3 · comparator · “cabozantinib” · registered Oct 2018
| Exelixis64% of its industry studiesUS: Exelixis (FDA 2012)EU: Ipsen (EMA 2014) | 22 studies | 23 studies | comparator 2 · background 5 |
atezolizumabRecent, repeatedEvidence- NCT07620574 · Exelixis · Phase 3 · live · background · “Atezolizumab” · registered May 2026
- NCT06090318 · Rain Oncology Inc · Phase 2 · background · “Atezolizumab” · registered Nov 2022
- NCT03961698 · Infinity Pharmaceuticals, Inc. · Phase 2 · live · background · “Atezolizumab” · registered Apr 2019
- NCT03829501 · Sanofi · Phase 2 · background · “Atezolizumab” · registered Jan 2019
| Hoffmann-La Roche91% of its industry studiesUS: Hoffmann-La Roche (FDA 2016)EU: Hoffmann-La Roche (EMA 2017) | 22 studies | 22 studies | background 4 |
casdatifanRecent, repeatedEvidence- NCT07293351 · Bristol-Myers Squibb · Phase 2 · live · background · “Casdatifan” · registered Dec 2025
- NCT07227415 · Pfizer · Phase 2 · live · background · “Casdatifan” · registered Nov 2025
| Arcus Biosciences, Inc.78% of its industry studies | 22 studies | 22 studies | background 2 |